Šoupal Jan, Prázný Martin
Vnitr Lek. 2015 Apr;61(4):291-4.
SGLT2 and DPP4 inhibitors are new effective oral antidiabetic drugs with low risk of hypoglycemia and positive or neutral impact on body weight. These characteristics are substantially different from more widely used sulphonyl-ureas. Current treatment of type 2 diabetes is rather complicated. Moreover, the position of new antidabetics in the guidelines has not yet been clearly defined. Personalised treatment on the basis of molecular markers is still not possible. Therefore, the position of new antidiabetics in the treatment of type 2 diabetes is often determined by clinical experience and subsequently modified by new clinical studies. Currently, doctors are asking which of these modern antidabetics to choose. The following text might help in this decision.
钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和二肽基肽酶4（DPP4）抑制剂是新型有效的口服抗糖尿病药物，低血糖风险低，对体重有积极或中性影响。这些特性与更广泛使用的磺脲类药物有很大不同。2型糖尿病的当前治疗相当复杂。此外，新型抗糖尿病药物在指南中的地位尚未明确界定。基于分子标志物的个性化治疗仍然无法实现。因此，新型抗糖尿病药物在2型糖尿病治疗中的地位通常由临床经验决定，随后由新的临床研究进行修正。目前，医生们在问该选择这些现代抗糖尿病药物中的哪一种。以下文字可能有助于做出这一决定。
